Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma

BACKGROUND: Our purpose was to evaluate thymidine synthase (TS), thymidine phosphorylase (TP), and excision repair cross-complementation group 1 (ERCC1) expression as biomarkers for capecitabine and cisplatin (XP) combination chemotherapy in patients with metastatic oesophageal squamous cell cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, S, Park, Y H, Kim, K H, Cho, E Y, Ahn, Y C, Kim, K, Shim, Y-M, Ahn, J S, Park, K, Im, Y-H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966625/
https://www.ncbi.nlm.nih.gov/pubmed/20700125
http://dx.doi.org/10.1038/sj.bjc.6605831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966625/
https://www.ncbi.nlm.nih.gov/pubmed/20700125
http://dx.doi.org/10.1038/sj.bjc.6605831

Ejemplares similares